Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
06:36pm, Friday, 26'th Dec 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and o
Omeros (NASDAQ:OMER) Hits New 12-Month High – Time to Buy?
04:26am, Thursday, 25'th Dec 2025
Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) hit a new 52-week high on Thursday. The stock traded as high as $17.65 and last traded at $15.0850, with a volume of 24509175 shares trade
Traders Purchase Large Volume of Call Options on Omeros (NASDAQ:OMER)
01:44am, Thursday, 25'th Dec 2025
Omeros Corporation (NASDAQ: OMER - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 29,728 call options on the company. This is an incr
Why Omeros Stock Skyrocketed Today
05:22pm, Wednesday, 24'th Dec 2025
It won approval for a medicine that treats a potentially fatal complication from stem cell transplants. This is the first drug approved for that indication.
Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely
02:14pm, Wednesday, 24'th Dec 2025
Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation. Yartemlea is the first and only approved therapy for TA-TMA, showing high
Gold Edges Lower; Omeros Shares Jump
12:21pm, Wednesday, 24'th Dec 2025
U.S. stocks traded higher midway through trading, with the Dow Jones index surging more than 200 points on Wednesday.
FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication
11:01am, Wednesday, 24'th Dec 2025
The FDA has approved Omeros Corporation's Yartemlea for TA-TMA, a fatal complication of stem-cell transplantation, with a 61% success rate.
US FDA approves Omeros' drug to treat dangerous transplant complication
09:05am, Wednesday, 24'th Dec 2025
The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication, marking the first treatment to be greenlit for the condition, the company said on Wednesday.
FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
09:00am, Wednesday, 24'th Dec 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoie
Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of “Moderate Buy” from Brokerages
01:10am, Monday, 08'th Dec 2025
Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have received an average rating of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat reports. O
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (
Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript
10:37am, Monday, 17'th Nov 2025
Omeros Corporation ( OMER ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Gregory Demopulos - Co-Founder, Chairman, CEO & President David Borges - VP of Finance, Chief Accou
Omeros Corporation Reports Third Quarter 2025 Financial Results
04:11pm, Thursday, 13'th Nov 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which includ
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
08:30am, Tuesday, 11'th Nov 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025,
Breakout Momentum Plays You Need to Know About
08:17am, Thursday, 23'rd Oct 2025
Momentum investors rely on a combination of astute analysis and timing to maximize gains. While this approach can carry a fair degree of risk, the allure of identifying a fast-growing stock and joinin
